# Denteric

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/denteric-pty

- Industry: Biotechnology
- Headquarters: Melbourne, Australia
- Website: www.denteric.com
- Total disclosed funding: $12M
- Latest round: Series A (May 20, 2019)
- Investors on record: 7

## About

Denteric Pty Ltd. is a biotechnology firm focused on developing precision immunotherapies to combat chronic infections associated with periodontal disease, particularly those caused by _Porphyromonas gingivalis_ (Pg).Founded in 2019 and headquartered in Melbourne, Australia, Denteric Pty Ltd. specializes in immunotherapy solutions for severe periodontal disease. The company raised AUD 17.5 million in Series A funding in May 2019, led by Medical Research Commercialisation Fund, with participation from several investors including AustralianSuper and CSL Limited. Denteric has completed one deal to date, achieving a current valuation of AUD 23.529 million.Denteric specializes in the development of precision immunotherapies targeting chronic infections caused by _Porphyromonas gingivalis_ (Pg), focusing on severe periodontal disease. Their flagship product neutralizes virulence factors produced by Pg that contribute to the progression of periodontal conditions. This therapy aims to improve patient outcomes and enhance oral health for healthcare professionals and patients, particularly in Australia, the United States, and parts of Europe.Denteric generates revenue through direct transactions with healthcare providers who administer its therapies. The structure is based on a direct-to-consumer model whereby healthcare professionals prescribe Denteric's therapies as part of treatment plans. The company collaborates with dental clinics and hospitals that integrate its therapies, ensuring an effective revenue model supported by demand from patients and healthcare professionals seeking advanced treatment options.Denteric plans to utilize the recent AUD 17.5 million Series A funding secured in May 2019 to accelerate the development of new immunotherapy products targeting periodontal disease. The company is also exploring entry into additional markets, specifically targeting European countries by 2024, to expand its reach and operational footprint. This strategic funding will support the development and launch of innovative solutions aimed at improving oral health outcomes.

## Funding rounds

- Series A, May 20, 2019, $12M — Hostplus, Brandon Capital Partners, AustralianSuper, Medical Research Commercialisation Fund, United News of India, CSL, Um Commercialisation Pty Ltd

## Investors

- Hostplus — Series A
- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Series A
- AustralianSuper — Series A
- Medical Research Commercialisation Fund — Series A
- United News of India — Series A
- CSL — Series A
- Um Commercialisation Pty Ltd — Series A